Results
Sensory neuron differentiation and characterization. We obtained 107 iPSC lines derived from unrelated, apparently healthy individuals by the Human Induced Pluripotent Stem Cells Initiative (HIPSCI) resource (http://www.hipsci.org) 8 , and followed an established small-molecule protocol 7 to differentiate them into sensory neurons of a nociceptor phenotype (Fig. 1a and Supplementary  Tables 1-3) . We carried out 123 differentiations, 13 with an early version of the protocol (P1) that was subsequently refined (P2) to reduce the number of differentiation failures. After quality control exclusions ( Supplementary Fig. 1 ), we had gene expression data for 119 differentiations from 100 unique iPSC donors; all analyses apart from QTL calling focused on the 106 P2 samples only.
We clustered our gene expression data with data from 239 iPSC samples from many of the same donors, 28 postmortem DRG tissue samples from ten donors, and 44 primary tissues from the GTEx project 9 (Fig. 1b) . Globally, IPSDSN samples were most similar to iPSCs (gene expression correlation Spearman ρ = 0.89), followed by DRG (ρ = 0.84). Because different gene expression quantitation methods were used in the GTEx project, we cannot be certain of relative similarities between GTEx tissues and the samples we uniformly processed (IPSDSNs, iPSCs, and DRG). The similarity to iPSCs may reflect a lack of maturity in IPSDSNs, which is a well-recognized problem with iPSC-derived cells [10] [11] [12] [13] . We also note that because the same iPSCs were differentiated to IPSDSNs, both donor genetic background and cell culture effects may have
Molecular and functional variation in iPSC-derived sensory neurons
contributed to the observed similarity. Despite this, key sensory neuronal marker genes were expressed at high levels in IPSDSNs, whereas pluripotency genes were not (Fig. 1c) . By carrying out Ca 2+ flux measurements on a subset of differentiated cultures (n = 31), we confirmed that the cells consistently responded to the sodium ion channel modulators veratridine and tetrodotoxin ( Supplementary Fig. 2 ). Patch-clamp electrophysiology of 616 individual neurons from 31 donors (Supplementary Figs. 3 and 4) showed that the distribution of rheobases was similar to that in primary DRG cells, but with substantial variation between donors ( Supplementary Fig. 5 ).
Quantifying differentiation variability with single-cell RNA-seq.
In previous work we showed that not all individual cells express neuronal marker genes after differentiation 7 . Samples also appeared to differ visually in the fraction of cells with a neuronal morphology. To characterize this heterogeneity, we sequenced 177 IPSDSNs from one individual and clustered them on the basis of their expression profiles with SC3 14 . The data were best explained by two clusters ( Fig. 2a and Supplementary Fig. 6 ), with 63% of cells forming a tight cluster expressing sensory-neuronal genes (e.g., SCN9A, CHRNB2), and the remaining 37% of cells forming a looser cluster expressing genes typical of fibroblasts (e.g., MSN, VIM). The two cell types were also cleanly separated in a principal components plot ( Supplementary Fig. 7 ), which indicated that the cells differentiated to distinct cell states. Gene expression in the neuronal cluster was most similar to that in DRG (Spearman's ρ = 0.654), followed by iPSCs (ρ = 0.609) ( Supplementary Fig. 8 ), whereas the fibroblastlike cluster was most similar to GTEx fibroblasts (ρ = 0.683), DRG (ρ = 0.662), and iPSCs (ρ = 0.653).
Next, we used CIBERSORT 15 to estimate the fraction of RNA from neuronal cells in our bulk RNA-seq samples, using the singlecell gene expression counts as signatures of neuronal or fibroblastlike expression. The estimated neuronal content correlated strongly (R 2 = 0.75) with the first principal component of gene expression, and this corresponded well with a visual assessment of neuronal content in microscopy images ( Fig. 2b and Supplementary Figs. 9 and 10). Although CIBERSORT estimated relatively high fibroblast-like content for many samples (mean, 49%), the greater RNA content (2.3-fold greater; Supplementary Fig. 11 ) of fibroblast-like cells may have been a contributing factor in this. Indeed, when the single-cell counts were pooled, CIBERSORT estimated the fibroblast content of this 'sample' as 60%, considerably higher than the 37% of single cells in the fibroblast-like cluster. Despite this, IPSDSN samples with high estimated fibroblast content still showed greater similarity to DRG in terms of genome-wide gene expression than they did to any GTEx tissue, including fibroblast cell lines (Supplementary Fig. 12 ). Fig. 13 ). However, differentiation replicates within donor cell lines did not cluster together consistently ( Supplementary Fig. 14) , which suggests that variability due to differentiation was at least as high as that due to donor genetic background and iPSC reprogramming together. Indeed, we observed a high degree of heterogeneity in the expression levels of some genes compared with that in DRG ( Fig. 1c and Supplementary  Fig. 15 ). These observations were independent of sample size, and were robust when we considered DRG samples from unique donors only ( Supplementary Fig. 16 ). Next, we compared between-sample variability in global gene expression of IPSDSNs, measured as the coefficient of variation (CV) for each gene, to that for other somatic tissues and cell lines. The distribution of gene CVs in IPSDSNs (median CV: 0.37) fell within the range of values for most GTEx tissues (Fig. 3a) but was considerably higher than in DRG (median CV: 0.23), thus indicating that IPSDSNs have greater between-sample variability in expression than the primary tissues they are intended to model. Highly variable genes in IPSDSNs were enriched for function in neuronal differentiation and development (Supplementary Table 4 ), whereas developmental genes were not highly variable in DRG, iPSCs, or GTEx nervous tissues ( Supplementary Fig. 17 ). Genes that were upregulated between iPSCs and IPSDSNs (1% FDR and at least fivefold higher), which included those essential for sensory neuronal function, were also more variable than the remaining genes ( Supplementary Fig. 18 ). These results demonstrate that expression of neuronal genes varies substantially more in IPSDSNs than in somatic nervous tissue, probably as a result of variability in differentiation. Consistent with this, variance components analysis ( Fig. 3b and Supplementary Fig. 19 ) showed that more variation was explained by differentiation batch (median: 24.7%) than by donor/iPSC line of origin (median: 23.3%), which includes both donor and reprogramming effects.
iPSC culture conditions influence cell fate. Our variance components analysis suggested that the starting iPSC cell culture conditions influenced gene expression patterns in the IPSDSNs produced 4 weeks later (Fig. 3) . Of the 106 successful P2 differentiations, 27 were from iPSCs maintained on mouse embryonic fibroblast feeder cells (feeder iPSCs), and the remaining 79 were grown in Essential 8 medium (E8 iPSCs). The first principal component (PC) of iPSC gene expression clearly differentiated feeder and E8 iPSCs (Fig. 3e) , indicating that culture conditions have some of the greatest global effects on transcription. Similarly, PC1 of gene expression in IPSDSNs distinguished samples originating from feeder versus E8 iPSCs; moreover, IPSDSNs from E8 iPSCs had higher neuronal content ( Fig. 3f ; 28% higher for E8 iPSCs; t-test P = 1.84 × 10
−5
). A possible technical explanation for these results is that protocol implementation and batch effects changed subtly over the course of the project. However, the difference in neuronal content between IPSDSNs derived from E8 iPSCs and those from feeder iPSCs remained when we included the sample derivation date as an explanatory covariate (linear regression P = 6.5 × 10 −4 ; 36% higher for E8 iPSCs; Supplementary Fig. 20 ).
Next, we identified genes that were differentially expressed between E8 and feeder iPSCs (Fig. 3c,d) . Genes upregulated in feeder iPSCs were strongly enriched for mesenchyme development, stem cell differentiation, and Wnt and TGF-β signaling (Supplementary Tables 5-7) . Notably, inhibition of TGF-β /SMAD signaling is a key step in sensory neuronal differentiation. The top differentially expressed genes included early developmental regulators EMX1 (15-fold higher in E8 iPSCs), which is important for specific neuronal cell fates, and BMP2 (13-fold higher in feeder iPSCs), which has been shown to suppress differentiation to sensory cell fates by antagonizing Wnt/β -catenin 16 ( Fig. 3e ). In addition, sensory neuronal markers SCN9A and TAC1 were expressed at low levels in iPSCs, with 2.2-fold and 2.9-fold higher expression in E8 iPSCs, respectively. We also considered genes that were differentially expressed between E8-iPSC-derived and feederiPSC-derived IPSDSNs (Fig. 3d) . Genes upregulated in IPSDSN samples from feeder iPSCs were overrepresented in extracellular matrix components, pattern specification, and Wnt signaling ( Fig. 3f and Supplementary Tables 8-10 ). Genes upregulated in IPSDSN samples from E8 iPSCs were overrepresented in ion channel complexes, peripheral nervous system development, and synapse organization. These differences probably reflect the increased neuronal content of samples from E8 iPSCs. Together, these results suggest that iPSCs are primed for different cell fates depending on the iPSC culture medium. Because iPSC culture conditions influenced differentiation outcomes, we examined gene expression variability within subsets of IPSDSN samples. IPSDSNs differentiated from feeder iPSCs had somewhat higher global gene expression variability than those from E8 iPSCs, but those from E8 iPSCs were still highly variable relative to DRG and iPSCs ( Supplementary Fig. 21 ), with neuronal and developmental gene sets enriched for highly variable genes (Supplementary Table 11 ).
Genetic variants influence gene expression, splicing, and chromatin accessibility in sensory neurons. Using a linear model (FastQTL 17 ), we mapped 1,403 expression quantitative trait loci (eQTLs) at a false discovery rate (FDR) of 10%. This number of eQTLs was lower than that in GTEx tissues of similar sample size ( Supplementary   Fig. 22 ), which suggested that the power for eQTL discovery had been reduced because of variability introduced by differentiation. Using the allele-specific method RASQUAL 18 , we detected 3,778 genes with expression-modifying genetic variants, termed eGenes, at an FDR of 10% (Supplementary Table 12 ). Notably, the improvement in power from the use of allele-specific signals was greatest among genes with high variability across samples ( Supplementary Fig. 23 ).
We next compared our eQTLs with those in GTEx. When tissues were clustered on the basis of pairwise correlation in eQTL effect sizes, IPSDSNs clustered most closely with GTEx brain tissues, while also showing elevated correlation with GTEx fibroblasts ( Supplementary Fig. 24 ). Of the 3,778 eGenes, 954 showed little or no association in GTEx v6p (Supplementary Table 13 ), genes, the estimated fraction of total expression variability across samples due to differentiation batch, donor genetics or iPSC reprogramming, culture conditions ("wasFeeder": feeder-dependent versus E8 medium), and gender. Individual points represent outlier genes. c, Genes that were differentially expressed (1% FDR; blue and red points) between iPSC samples grown on feeders (n = 68) and those grown in E8 medium (n = 171). d, Genes that were differentially expressed (1% FDR; blue and red points) between IPSDSNs from feeder iPSCs (n = 27) and those from E8 iPSCs (n = 79). Neuronal differentiation genes, such as RET and L1CAM, were expressed at higher levels in samples from E8 iPSCs. e, Left: global gene expression differences between feeder and E8 iPSCs are captured in PC1. Middle and right: expression of selected differentially expressed genes. f, Left: the estimated neural fraction of samples differed in IPSDSNs derived from feeder versus E8 iPSCs. Middle and right: expression of selected differentially expressed genes. Box plots show the median (center line) and the 25th and 75th percentiles (box edges), with whiskers extending to 1.5 times the interquartile range.
and these included genes with known involvement in pain or neuropathies, such as SCN9A, GRIN3A, and NTRK2, which suggests that these genes have regulatory variants with IPSDSNspecific functions.
Variants that affect gene splicing (sQTLs) often change either protein structure or context-dependent gene regulation, and may be more enriched for complex trait loci than are eQTLs 19 . Using the annotation-free method LeafCutter 20 followed by FastQTL 17 , we discovered QTLs for 2,079 alternative splicing clusters at an FDR of 10% (Supplementary Table 14) . Notably, only 538 (26%) of the lead variants for these splicing associations were in linkage disequilibrium (LD) (r 2 ≥ 0.5) with an eQTL in our dataset, indicating that these sQTLs are not merely proxies for gene-level eQTLs (or vice versa).
We collected ATAC-seq data for 31 samples 21 and used them to map 6,318 chromatin accessibility QTLs (caQTLs) at an FDR of 10% (Supplementary Table 15 ). Using the LOLA Bioconductor package 22 , we found strong enrichment of our tissue-specific lead QTL single-nucleotide polymorphisms (SNPs), relative to GTEx lead SNPs, within peaks for SMARCB1 and SMARCC2 (odds ratios, 5.8 and 14.1; P < 5 × 10
; Supplementary Tables 16 and 17) , which are both members of the neuron-specific chromatin remodeling (nBAF) complex 23 . IPSDSN eQTLs and ATAC-seq peaks were enriched for ELK1 and ELK4 binding, as well as c-Fos, a target of ELK1 and ELK4 that is widely expressed but known to have specific functions in sensory neurons 24, 25 (Supplementary Table 18 ).
Sensory neuron QTLs overlap with complex trait loci.
Although we were interested in comparing our QTLs with data from genomewide association studies (GWASs) for pain, the largest such GWAS carried out to date included just 1,308 samples and found no associations at genome-wide significance 26 . We therefore considered all GWAS catalog associations with P < 5 × 10 −8 that were in high LD (r 2 > 0.8) with a QTL in our dataset to (i) determine whether any GWAS traits are enriched overall for overlap with sensory neuron QTLs, and (ii) find individual QTLs that are strong candidates to mediate a GWAS association. Overall, IPSDSN eQTLs were enriched for overlap with GWAS catalog SNPs (P < 0.001) relative to 1,000 random sets of SNPs matched for minor allele frequency, distance to nearest gene, gene density, and LD 27 , and the overlap was consistent with that seen for eQTL studies in other tissues ( Supplementary Fig. 25 ). Although nociceptive neurons are specialized for sensing pain signals, one might expect enrichment for traits known to involve the nervous system more generally. However, among the 41 traits with at least 40 GWAS catalog associations, no trait had significantly greater overlap with our QTLs than the other traits did after correction for multiple testing (Supplementary Table 19) .
Across all traits, we found 156 eQTLs that overlapped at least one GWAS association, as well as 129 sQTLs and 172 caQTLs with GWAS overlap (Supplementary Tables 20-22 ). Among overlapping associations we found a number that related to neuronal diseases. One striking overlap was between an eQTL for SNCA, which encodes α -synuclein, and Parkinson's disease, for which a likely causal variant was recently identified 10 . The lead GWAS SNP and our lead eQTL were both in perfect LD with rs356168, in an intron of SNCA. Soldner et al. 10 used CRISPR-Cas9 genome editing in iPSC-derived neurons to show that rs356168 alters both SNCA expression and binding of brain-specific transcription factors. In IPSDSNs, we found that the G allele of rs356168 increased SNCA expression 1.14-fold, in line with a previous report of 1.06-fold to 1.18-fold increases in neurons and neural precursors 10 . Although it resided in a visible ATAC-seq peak in our data, rs356168 was not a caQTL (raw P = 0.22). eQTLs for SNCA are reported in GTEx (v6p), but none of the tissue lead SNPs are in LD (r 2 > 0.2) with rs356168, which suggests that this SNP's effect can be more readily detected in IPSDSNs and in the frontal cortex tissue and iPSC-derived neurons studied by Soldner et al. 10 . We also found multiple compelling overlaps between sQTLs and GWAS associations (Fig. 4) . A strong sQTL for TNFRSF1A (P = 9.9 × 10 −29
) had the same lead SNP (rs1800693) as a multiple sclerosis association. This SNP has been experimentally shown to cause skipping of exon 6, which results in a truncated, soluble form of TNFR1 that appears to reduce TNF levels 28 . TNFRSF1A shows high expression ( > 15 fragments per kilobase of transcript per million mapped reads (FPKM)) in both IPSDSNs and DRG, as well as in cells of the immune system. TNF signaling has been shown to have both inflammatory and neuroprotective effects in the central nervous system, and, despite a large body of research, the exact mechanisms and cell types responsible for the genetic risk associated with TNF receptor polymorphisms remain unclear 29 .
An sQTL for SIPA1L2 (rs16857578) was in LD with associations for both Parkinson's disease (rs10797576; r 2 = 0.93) and blood pressure (rs11589828; r 2 = 0.94). An unannotated noncoding exon (chr1:232533490-232533583) between alternative SIPA1L2 promoters was included in nearly 50% of transcripts in individuals with the reference genotype, but splicing in of the exon was abolished by the variant (Fig. 4b) . SIPA1L2, also known as SPAR2, is a Rap GTPase-activating protein known to be expressed in the brain and enriched at synaptic spines 30 , although its function is not yet clear. Interestingly, the related protein SIPA1L1 has an alternative isoform with an N-terminal extension that is regulated post-translationally to influence neurite outgrowth 31 . A complex sQTL for APOPT1 (rs4906337) was in near-perfect LD with a schizophrenia association (rs12887734). The splicing events involved skipping of either exon 3 only or exons 2 and 3 ( Fig. 4c) . At least 20 variants were in high LD (r 2 > 0.9), including rs4906337, 40 bp from the exon 3 acceptor splice site, and rs2403197, 63 bp from the exon 4 donor splice site. APOPT1 is localized to mitochondria, and homozygous loss-of-function mutations lead to cytochrome c oxidase deficiency, with affected individuals having variable motor and cognitive impairments and peripheral neuropathy 32 .
Recall-by-genotype studies in iPSC-derived cells will require large sample sizes. One attractive use of iPSCs is to experimentally characterize GWAS loci via a 'recall-by-genotype' approach. In this method, iPSC lines with specific genotypes are chosen from a large bank and differentiated into target cell types (for an example, see the study by Warren et al. 12 ). Our observations suggested that the cellular heterogeneity introduced by differentiation could affect the power of these studies to detect the effects of common genetic variants. Our large set of differentiations gave us accurate genome-wide estimates of effect size and expression variability in an iPSC-derived cell type. We investigated the performance of iPSC-based recallby-genotype studies by bootstrap resampling from a stringent (1% FDR) IPSDSN eQTL call set. For each eGene, we sampled expression counts from an equal number of major and minor homozygotes for the lead SNP, sampling with replacement to achieve a specific sample size. We then estimated power as the fraction of 100 bootstrap replicates with a significant difference (P < 0.05, two-tailed Wilcoxon rank sum test) in expression between homozygotes.
Our results illustrate important trends. First, recall-by-genotype studies in iPSC-derived cells are likely to require relatively large sample sizes-typically 20-80 unrelated individuals-for variants with an allelic fold change between 1.5-fold and 2-fold (Fig. 5a ). Second, highly variable genes are more challenging, with power below 40% with a sample size of 20 for even moderately variable genes (CV of 0.5-0.75). Although expression noise will not typically be known accurately a priori, an estimate of effect size may be available from previous eQTL studies, which in principle could enable estimation of the sample size required to achieve a desired power. Note that these power estimates assume that a single gene is being tested, which implies a very strong prior belief in the causal gene in the region. When multiple genes are tested, power will be further reduced. Large sample sizes will probably also be required when genome editing is used to identify causal GWAS-associated variants: although genetic background can be controlled in such an experiment, differentiation noise will continue to be a major contributor to gene expression variability.
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Discussion
iPSC-derived cells enable scientists to study the molecular mechanisms of disease in relevant human cell types, including those that are inaccessible as primary tissue samples. Because common disease-associated risk alleles tend to have small effect sizes, it is challenging to observe their effects in cellular models 10, 11 . In an iPSC-based system, this difficulty is compounded by variability between samples in the success of differentiation, as described for hepatocytes 33 , hematopoietic progenitors 34 , and neurons 35, 36 . Our study is the first that we are aware of in which iPSCs were differentiated to a neuronal cell type and the resulting cells were functionally characterized at scale. Sample-to-sample variability in gene expression in the iPSC-derived cells was greater than that in DRG, with highly variable genes enriched in processes related to neuronal differentiation and development. This highlights that genes likely to be of particular interest and relevance for the function of these cells are also among the most variable, a complication that may be broadly true of iPSC-derived cells. We detected thousands of eQTLs, sQTLs, and caQTLs in IPSDSNs, using a model that combines allele-specific and between-individual differences in expression to improve power for association mapping. Some of these overlapped known expression-modifying variants associated with disease, such as an eQTL for SNCA associated with Parkinson's disease. However, for most of these disease overlaps, the causal variants are not known and await in-depth dissection of individual loci in iPSC-derived neurons.
Our study highlights the potential power of iPSC-derived cells for studies of human genetic variation, but it also illustrates the limitations of this approach. First, despite the fact that IPSDSNs express key marker genes and exhibit neuronal morphology and electrophysiology, they are transcriptionally distinct from DRG. This reflects a limitation of existing in vitro differentiation protocols, which produce cells that are not as functionally or transcriptionally mature as primary tissues. Second, our differentiations did not produce pure populations of neurons. Although we used single-cell RNA-seq to estimate neuronal content in bulk IPSDSN samples, we could not measure the purity of the resulting cultures precisely. Some of the sample-to-sample variability that we observed was probably due to this mixture of cell types, which varied across differentiations. Mature neurons can be labeled for marker genes but are not easily sorted by automated systems, and thus the highthroughput options available for purifying neuronal populations are limited. As a result, our QTLs do not represent those of a pure sensory neuronal cell type. For many cell types, sorting could provide one solution to the heterogeneity of differentiated cell populations.
The similarity of the fibroblast-like single cells to DRG raises the question of whether these cells were immature sensory neurons. Single-cell sequencing at multiple time points during MYOD-mediated myogenic reprogramming has suggested that some cells traverse a desired course, whereas others terminate at incomplete or aberrant reprogramming outcomes 37 . Such an approach in IPSDSNs could identify determinants of neuronal differentiation trajectories, and may yield insights for protocol changes to improve the purity of differentiated neurons or to specify more precise neuronal subtypes. More generally, replacing bulk RNA-seq with single-cell sequencing across many samples could enable in silico sorting of cells on the basis of their transcriptomes, and better characterization of the sources of variation in a differentiated population of cells. Further, culturing cells from multiple donors in a pool, along with a single-cell RNA-seq readout, could reduce differentiation-related batch effects while still allowing researchers to identify donor-specific genetic effects on gene expression. These advantages suggest to us that a move toward single-cell RNA-seq will be extremely useful in iPSC-derived cell models.
For iPSC models of common disease-associated variants to be used effectively, it is critical to know which variants exhibit a detectable cellular phenotype in vitro. We estimated the sample sizes needed to detect the effects of regulatory variants in iPSC-derived cells by using a recall-by-genotype design. Power greater than 80% was achieved only with large (40 + ) samples, even for alleles with a fold change of 1.5-2. Even larger samples will be needed when multiple genes in a GWAS interval are tested. These observations are consistent with a recent genome-editing experiment that required 136 differentiations in hepatocyte-like cells to discover an effect of rs12740374 on SORT1 gene expression 12 . Notably, the modest effect of this variant on expression in hepatocyte-like cells (1.3-fold increase) stands in contrast to the large effect of the variant (≥ 4-fold increase) observed previously in primary liver 38 . Where it is possible to use a coding SNP to assess the allele-specific effect of a genome edit, as done for SNCA 10 , this may prove a more efficient approach to detect causal effects of individual regulatory variants. In the future, improved differentiation protocols that show reduced variability will also make it easier to detect regulatory variant effects.
In summary, our catalog of QTLs highlights a large set of common variants and target genes with detectable effects in iPSCderived neurons. These associations provide promising targets for functional studies to fine-map causal disease-associated alleles, such as by allelic replacement using CRISPR-Cas9, and our study describes the importance of considering differentiation-induced variability when planning these studies in iPSC-derived cells.
URLs. CIBERSORT, http://cibersort.stanford.edu; ENCODE, http://www.encodeproject.org; GTEx, http://www.gtexportal.org; HIPSCI, http://www.hipsci.org.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-017-0005-8. Table 2 , and details of processes and assays for these iPSCs generated by the HIPSCI project are available at http://www.hipsci.org. Briefly, 107 human iPSC lines from 103 healthy donors were obtained from HIPSCI 8 . Of these, 38 were initially grown in feeder-dependent medium, and the remaining iPSCs were grown in feeder-free E8 medium. All HIPSCI samples were collected from consenting research volunteers recruited from the NIHR Cambridge BioResource (http:// www.cambridgebioresource.org.uk), initially under existing ethics rules for iPSC derivation (Regional Ethics Committee (REC) reference 09/H0304/77, v.2, 4 January 2013), with later samples collected under a revised consent (REC reference 09/H0304/77, v.3, 15 March 2013).
Methods iPSC lines. A summary of the iPSC lines used is available in Supplementary
Sensory neuron differentiation.
All differentiations in this study were carried out by a single individual, and a summary of the IPSDSN cell lines is in Supplementary  Table 1 . Two protocols were used, named P1 (13 differentiations) and P2 (110 differentiations). P1 protocol samples were included for QTL calling, and other analyses used P2 protocol samples exclusively. The P1 protocol (described previously 7 ) involved the addition of '2i' inhibitors (LDN193189 and SB-431542) for 5 d, followed by '5i' inhibitors (LDN193189, SB-431542, CHIR99021, DAPT, SU5402) for 6 d. When applying this protocol to a larger number of samples, we observed excessive cell death before obtaining neural progenitors (days 9-12). We altered the protocol to make it more similar to that of Chambers et al. 39 by doing the following: using E8 rather than mTeSR1 media when maintaining iPSCs before differentiation; phasing in neurobasal media beginning at day 4, and gradually increasing the amount to 100% by day 11;
beginning the addition of 5i inhibitors at day 3 rather than day 5; and stopping the addition of small-molecule inhibitors LDN193189 and SB-431542 beginning at day 7 rather than day 11; the three inhibitors that continued to be added were referred to as 3i inhibitors.
Functional assays (Ca 2+ flux and response to veratridine) confirmed that the responses of the sensory neurons produced by each protocol were equivalent; however, the P2 protocol performed more consistently across cell lines and culture parameters.
P2 protocol. All reagents were from Life Technologies unless otherwise indicated. Clump-passaged iPSCs were single-cell seeded in E8 media on growthfactor-reduced Matrigel (BD Biosciences) 48 h before neural induction (day 0). KSR media was prepared as 500 ml of DMEM-KO, 130 ml of Knockout Serum Replacement Xeno-Free, 1 × NEAA, 1 × Glutamax, and 0.01 mM β -mercaptoethanol (Sigma). KSR media containing small-molecule inhibitors LDN193189 (100 nM) and SB-431542 (10 µ M) was added to cells on days 0-3 to drive anterior neuroectoderm specification. From day 3, CHIR99021 (3 µ M), DAPT (10 µ M), and SU5402 (10 µ M) were also added to further promote neural crest phenotypes. N2B27 media was progressively phased in every 2 d from day 4. N2B27 media was prepared as 500 ml of Neurobasal medium, 5 ml of N2 supplement, 10 ml of B27 supplement without vitamin A, 0.01 mM β -mercaptoethanol (Sigma), and 1 × Glutamax. On day 7, the use of inhibitors LDN193189 and SB-431542 ceased, but CHIR99021, DAPT, and SU5402 continued to be added. On day 11 cells were reseeded at 150,000 cells/cm 2 in maturation media containing N2B27 media with human-β -NGF, BDNF, NT3, and GDNF (each at 25 ng/ml). Mitomycin-C treatment (1 µ g/ml) was used once at day 14 for 2 h to reduce the non-neuronal population. Cells were differentiated in T25 flasks for RNA and nuclei isolation, and seeded onto coverslips and 96-well plates for electrophysiology and Ca 2+ flux assays.
P1 protocol. All reagents and concentrations used for P1 were identical to those used in the P2 protocol; the difference was the timing of reagent addition. Clump-passaged iPSCs were single-cell seeded in mTeSR1 iPSC media (StemCell Technologies) on growth-factor-reduced Matrigel (BD Biosciences) 48 h before neural induction (day 0). KSR media containing LDN193189 and SB-431542 was added to cells on days 0-5. From day 5, CHIR99021, DAPT, and SU5402 were also added. As for the P2 protocol, cells were reseeded on day 11 and treated with Mitomycin-C on day 14.
Single-cell RNA-sequencing. Full details are in Supplementary Note 1. Briefly, blood-derived iPSCs from a single individual, who was not a HIPSCI donor, were differentiated to IPSDSNs in three batches via the P2 protocol and then matured for 8 weeks. This differed from the bulk RNA-seq samples, which were matured for 4 weeks. Although changes in gene expression are minor after 4 weeks of maturation 7 , this difference in maturity may have influenced our estimates of neuronal content in bulk samples. Dissociated cells were prepared with a Fluidigm C1 and the Illumina Nextera XT kit, and sequenced by Illumina Nextseq500 (2 × 75 bp). Reads were aligned to GRCh38 and Ensembl 80 transcript annotations with STAR v2.4.0d with the default parameters. We excluded nine cells that expressed fewer than 20% of the ~56,000 quantified genes, and then used SC3 14 to cluster the remaining 177 cells based on expression counts. We examined alternative numbers of clusters (k = 2-5; Supplementary Fig. 6 ). With two clusters, marker genes clearly identified one cluster (111 cells) as neuronal, whereas the other cluster (66 cells) had high expression of extracellular matrix genes reminiscent of fibroblasts. With three and four clusters, the sensory-neuronal cell cluster remained unchanged, and the fibroblast-like cluster became further subdivided. This suggests that a majority of the cells in this sample were terminally differentiated into sensory neurons, whereas the remaining cells were more heterogeneous in their gene expression.
Genotypes. We obtained imputed genotypes for all of the samples from the HIPSCI project. We used CrossMap (http://crossmap.sourceforge.net/) to convert variant coordinates from GRCh37 to GRCh38, and we used bcftools (http://samtools.github.io/bcftools/) to retain only biallelic variants (SNPs and insertions/deletions (indels)) with INFO > 0.8 and minor allele frequency (MAF) > 0.05 in the 97 samples used for QTL calling.
RNA-sequencing. The 131 RNA samples corresponded with 103 unique HIPSCI donors, as some samples were differentiation or RNA-extraction replicates. One sample failed in sequencing and was excluded. For QTL analyses, reads for each sample were aligned to GRCh38 and Ensembl 79 transcript annotations with STAR v2.4.0j with the default parameters. Using VerifyBamID (v1.1.2) 40 , we identified five mislabeled RNA samples for which the matching genotypes could be determined, as well as two samples with no matching genotypes that were ultimately excluded. For comparisons among tissues, we aligned reads to the 1000 Genomes GRCh37d5 reference with Gencode v19 transcript annotations by using STAR 2.5.3a.
Gene expression quantification, quality control, and exclusions. Gencode Basic transcript annotations, GRCh38 release 79, were downloaded from the GENCODE website (http://www.gencodegenes.org). Gene expression was counted for uniquely mapping reads with featureCounts (v1.5.0) 41 with options (-s 2 -p -C -D 2000 -d 25). A median of 45 million reads were generated per sample, with a median of 32.8 million reads (72%) uniquely mapping and assigned to genes. After excluding short RNAs and pseudogenes, we normalized expression counts for 35,033 genes using the conditional quantile normalization (CQN) R package cqn (v5.0.2) 42 . We determined pairwise correlation between samples by using normalized counts for 14,215 expressed genes (CQN > 1) and the first five principal components of gene expression against each other. We excluded four outlier samples from subsequent analyses (Supplementary Fig. 1 ), which left 126 samples from 97 donors. For QTL calling, replicate BAM files from same donor were merged using samtools.
To assess gene expression replicability, we determined the Spearman correlation coefficient of CQN-normalized expression between samples across all genes for (i) extraction replicates, (ii) differentiation replicates, and (iii) all possible pairs of samples from different donors, and then plotted the correlation coefficients in a histogram (Supplementary Fig. 13 ).
DRG samples and sequencing. Human tissue acquisition and handling were done at the Pfizer Neuroscience and Pain Research Unit in accordance with regulatory guidelines and ethical board approval. Postmortem human DRG were obtained in dissected form from Anabios or as an encapsulated sheath together with sensory/ afferent axons from National Disease Research Interchange and were subsequently dissected to isolate the cell-body-rich ganglion. The tissue was homogenized in QIAzol lysis reagent according to weight and processed according to the manufacturer's instructions for the Qiagen RNeasy Plus lipid-rich kit. RNA was prepared with the Illumina TruSeq stranded mRNA library prep kit and sequenced (2 × 100 bp reads) on the Illumina HiSeq 2500 system. Reads were aligned to GRCh37 with STAR, and gene counts and FPKM values were obtained with featureCounts and Ensembl v75 gene annotations.
Highly variable genes in IPSDSNs and GTEx samples.
For each of the 44 GTEx tissues, as well as IPSDSNs, DRG, and HIPSCI iPSCs, we considered the subset of genes expressed at RPKM > 1, and we calculated the CV of each gene's expression among samples of the same tissue (SMTSD in GTEx metadata). We plotted the distribution of CVs across all genes for each tissue as in Fig. 3a .
We used GeneTrail2 (https://genetrail2.bioinf.uni-sb.de) to do a gene set overrepresentation analysis for the top 1,000 most variable genes in IPSDSNs by CV (Supplementary Table 4) . Similarly, gene set over-representation analysis in E8 IPSDSN subsets was done with Genetrail2 and the top 1,000 most variable genes with RPKM > 1 (Supplementary Table 11 ).
Variance components analysis. For Fig. 3b , we selected the 106 P2 IPSDSN samples after quality control (QC) exclusions, and used DESeq2 to get FPKM values for each gene after size factor normalization. We included all genes with mean FPKM > 1, and input log 2 -transformed counts per sample into the variancePartition R package, with design formula (1|donor) + (1|differentiation) + (1|gender) + (1|wasFeeder). We plotted the distribution of variance explained for each gene across the four abovementioned factors, with unexplained variance shown as 'residuals' . For Supplementary Fig. 19a , we included 119 QC-passed samples and used variancePartition as described above, but with protocol in the design formula. For Supplementary Fig. 19b , we used 18 samples for which we had three differentiation replicates from each of six donor cell lines; all six iPSC lines were from females and had been cultured in E8 medium. We therefore included only donor and differentiation in the design formula.
Estimation of neuronal purity. We used CIBERSORT 15 to estimate the fraction of RNA from neuronal cells in our bulk RNA-seq samples. We used the 14,786 genes with mean CQN expression > 0 in bulk RNA samples, and retrieved raw counts for these genes in our single-cell RNA-seq data. We labeled the single-cell counts as "neuron" or "fibroblast-like" on the basis of the SC3 clustering, and used these as reference samples for CIBERSORT to generate custom signature genes. We used raw expression counts for the same genes for our 126 bulk RNA-seq samples as the mixture file for CIBERSORT to use in estimating the relative fractions of neuron and fibroblast-like cell RNA.
Correlation of iPSC and IPSDSN gene expression with cell culture conditions. We selected the 106 IPSDSN samples differentiated via the P2 protocol, as well as the 87 iPSC samples these were derived from and for which we had RNA-seq data, and we used DESeq2's variance-stabilizing transformation on the raw gene expression counts. We computed the first five PCs of gene expression separately in iPSCs and IPSDSNs, and used corrplot to compute pairwise correlations among these PCs and sample metadata: gender, iPSC passage number, iPSC culture conditions ('wasFeeder'), iPSC PluriTest score, IPSDSN fibroblast content, and IPSDSN processing date.
We used DESeq2 to determine which genes were differentially expressed between feeder iPSCs and E8 iPSCs, using expression counts for genes with median FPKM > 0.1 across iPSC samples (Supplementary Table 5 ). We removed associations driven by outliers, defined as a maximum Cook's distance ≥ 5. Similarly, we determined differentially expressed genes in IPSDSNs derived from either feeder iPSCs or E8 iPSCs (Supplementary Table 8 ), again for genes with median FPKM > 0.1. We used GeneTrail2 (https://genetrail2.bioinf.uni-sb.de) to do a gene set over-representation analysis for the 717 genes with expression at least twofold higher in feeder iPSCs than in E8 iPSCs, and similarly for the 631 genes with at least twofold higher expression in E8 iPSCs (Supplementary Tables 6  and 7) . We did an equivalent gene set over-representation analysis for the 1,159 genes with at least twofold higher expression in IPSDSNs differentiated from feeder iPSCs, and also for the 958 genes with at least twofold higher expression in IPSDSNs from E8 iPSCs (Supplementary Tables 9 and 10) .
To determine which genes were upregulated after differentiation from iPSCs to IPSDSNs, we selected the 19,658 genes with expression FPKM > 1 in at least two samples (iPSC or IPSDSN). We used DESeq2 as before, removing genes with maximum Cook's distance > 5, identifying 4,246 differentially expressed genes at an FDR of 1%.
QTL calling. Full details of QTL calling are provided in Supplementary Note 1. Briefly, to call cis-eQTLs, we first determined allele-specific read counts for each SNP within gene exons with GATK's ASEReadCounter 43 . We used RASQUAL's makeCovariates.R to identify 12 gene expression PCs to use as covariates. We ran RASQUAL 18 with the option --no-posterior-update for each of 35,033 genes, testing SNPs and indels (MAF > 0.05; INFO > 0.8) within 500 kb of the gene transcription start site. For each gene we applied Bonferroni correction to the P values according to the number of independent tests estimated by EigenMT 44 . We ran RASQUAL with the option --random-permutation to call QTLs with permuted sample labels, and noted the minimum EigenMT-corrected P value per gene. To determine the FDR for eQTL discovery at a given gene, we computed (#permuted data min p values < p)/(#real data min p values < p), where p is the minimum P value among SNPs for the gene in question. For QTL calling with FastQTL, we used CQN-transformed gene expression (cqn v5.0.2) 44 with a cis-window of 500 kb, including 20 PCs as covariates. We determined tissue-specific IPSDSN genes (not in GTEx) by using a protocol described for the HIPSCI project 8 . To call ATAC-seq QTLs, we used featureCounts v1.5.0 to count fragments that overlapped consensus ATAC-seq peaks, and ASEReadCounter to count allelespecific reads at SNPs within peaks. We ran RASQUAL for each of 381,323 peaks, testing SNPs and indels within 1 kb of the center of the peak. Because > 99.9% of peaks were less than 2 kb in size, this meant that we tested effectively all SNPs within peaks. We used an equivalent procedure to determine the FDR as for eQTLs.
Similarity of eQTLs with GTEx. Both GTEx samples and IPSDSNs had QTLs called with FastQTL. We selected lead eQTL variants in IPSDSNs for genes with expression ≥ 1 FPKM. We identified effect sizes for the same variants in each GTEx tissue, where these were available. We next determined the pairwise similarity between tissues in effect sizes for these variants (in R, cor() with "pairwise.complete.obs"). IPSDSNs were a significant outlier, having lower pairwise similarity to all GTEx tissues than they had to each other, probably because of the different expression quantification methods used in the two projects. We therefore determined the relative similarity of effect sizes across tissues by Z-scaling each row of the tissue correlation matrix and plotting the result (Supplementary Fig. 24 ).
Motif enrichment analyses. We used the R package LOLA 23 to identify enrichments in transcription factor binding sites (TFBSs) and motifs. We defined three sets of loci to consider for enrichment: (i) tissue-specific eQTL SNPs with a window of 50 bp ( ± 25 bp) around the SNP position; (ii) all eQTL SNPs (50-bp window); and (iii) all ATAC-seq peaks. For the QTLs, we used all GTEx eQTL lead SNPs as the 'universe' against which we tested TFBSs for enrichment. For this, we loaded GTEx eQTLs in R and used the liftOver function from rtracklayer to convert their coordinates to GRCh38. We tested for enrichment against the LOLA core database, considering only ENCODE TFBS enrichments (Supplementary  Tables 16 and 17 ). We also tested ATAC-seq peaks for enrichment relative to DNase hypersensitivity sites for many tissues from Sheffield 45 , which are available in the LOLA catalog. Motif enrichments in ATAC-seq peaks are reported in Supplementary Table 18 .
Power simulations. Gene expression values were normalized to counts per million. We selected the 544 eGenes discovered by RASQUAL at an FDR of 1% where at least ten P2 samples were homozygous for each allele of the lead eQTL variant, mean expression among homozygous carriers was consistent with RASQUAL's reported direction of effect, and CV < 2.
For each gene, we resampled the normalized expression values, with replacement, from IPSDSN samples to achieve a specified number of samples (N ∈ {4, 6, 10, 20, 40}) with each homozygous genotype. From 100 such resamplings, we defined the power to discover a given variant's effect as the fraction of cases with P < 0.05 from a Wilcoxon rank sum test comparing expression in each genotype category. We determined the allelic fold change between genotypes using RASQUAL's effect size (pi) as follows:
QTL overlap with GWAS catalog. Full details of the method used to determine QTL overlap are in Supplementary Note 1. Briefly, we used VCFtools (v0.1.14) 46 to compute the genotype correlation R 2 across our samples between GWAS catalog variants and lead eQTL, sQTL, and caQTL variants within 500 kb of each other, and retained only overlaps with R 2 > 0.8. We report all overlaps with GWAS associations having P < 5 × 10 −8 in Supplementary Tables 20-22 . To determine whether our QTLs were enriched for specific GWAS catalog traits, we grouped related traits and accounted for duplicate overlaps (Supplementary Note 6), and counted the number of unique GWAS-QTL overlaps for eQTLs, sQTLs, and caQTLs (Table 1) . For 41 traits with at least 40 GWAS catalog associations, we then considered the binomial probability of the observed overlap, with the expected frequency being the proportion of QTL overlaps among all trait associations (6.2%). After correction for multiple testing, no traits showed significantly greater overlap with our QTL catalog than other traits did.
To test for overall enrichment of QTLs overlapping GWAS catalog SNPs, we used VCFtools to identify 1000 Genomes SNPs in LD (r 2 > 0.8) with a GWAS catalog SNP. We used our IPSDSN eQTL lead SNPs as input to SNPsnap (https:// data.broadinstitute.org/mpg/snpsnap/) and computed 1,000 random sets of SNPs matched for LD partners, MAF, gene density, and distance to nearest gene. IPSDSN eQTL lead SNPs had more overlaps (92) with GWAS catalog and r 2 > 0.8 SNPs than did any of the matched sets (median, 58; range, 37-87).
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary. Describe how sample size was determined. QTL studies of fewer than 100 samples are common. The number of associations discovered is a function of sample size, so the sample size chosen is a function of cost and scope rather than power for specific effect sizes.
Data exclusions
Describe any data exclusions. Sensory neuron differentiation and characterisation, paragraph 1, and Supplementary Note.
Replication
Describe whether the experimental findings were reliably reproduced. QTLs were called using criteria for genome-wide significance at a chosen false discovery rate. Other analyses have not been replicated in independent samples.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
N/A
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
N/A
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
